Legislative Proposals of the Drug Illegal Acts and Torts Based on the Revise of the Drug Administration Law of PRC

Abstract

Abstract: Objective To compare the definitions, legal liabilities of drug illegal acts and torts in US and Europe, so as to provide reference for building drug responsibility legal system in our country. Methods Using the method of literature study and comparative study, this paper discusses the drug illegal acts and torts in different laws. Results Illegal acts and torts refer to administrative regulation and product liability, at present, the Drug Administration Law in our country pays close attention to drug quality constraint mechanism and administrative compliance, but Product Quality Law and Tort Law are Lack of effective connect of liability system. At the same time, the definitions of defect and illegal acts are imperfect, and the compensation doesn't consider the badness degree of the illegal behavior and the damage consequence. So there are many problems in the judicial practice and law enforcement operations. Conclusion Our country should take steps to define drug illegal acts and torts clearly, revise the regulations to guide the management of drugs, to make sure of the safety of public health.

Key words: drug illegal acts, counterfeit drugs, torts, law revision

CLC Number:

R951

LI Ming-shi,YANG Yue. Legislative Proposals of the Drug Illegal Acts and Torts Based on the Revise of the Drug Administration Law of PRC[J]. Chinese Journal of Pharmacovigilance, 2015, 12(3): 150-155.

References

[1] Federal Food, Drug, and Cosmetic Act(FD&C Act). Chapter II §321- Definitions; generally(g)(2)[S/OL]. (1938-01-25)[2014-10-27].http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/html/USCODE-2010-title21-chap9-subchapII.htm.
[2] Federal Food, Drug, and Cosmetic Act (FD&C Act). Chapter V §351Adulterated drugs and devices [S/OL]. (1938-01-25)[2014-10-27]. http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/html/USCODE-2010-title21-chap9-subchapV-partA-sec351.htm.
[3] Federal Food, Drug, and Cosmetic Act (FD&C Act). Chapter III§303. Penalties[S/OL].(1938-01-25)[2014-10-27].http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/html/USCODE-2010-title21-chap9-subchapIII-sec333.htm.
[4] EDQM. Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health[S/OL].(2011-10-28)[2014-10-27]. http://conventions.coe.int/Treaty/EN/Treaties/Html/211.htm.
[5] EMA. Directive 2011/62/EU of The European Parliament And of The Council of 8 June 2011[S/OL].(2011-07-08)[2014-10-27]. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:174:0074:0087:EN:PDF.
[6] EMA. Directive 2011/62/EU of The European Parliament And of The Council of 8 June 2011[S/OL].(2011-07-08)[2014-10-27].http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:174:0074:0087:EN:PDF.
[7] The United Kingdom Parliament. Medicines Act[S/OL].Part III.(1968)[2014-10-27].http://www.legislation.gov.uk/ukpga/1968/67/section/63.
[8] EMA. Council Directive of 25 July 1985(85/374/EEC).Article 6 [S/OL].(1985-07-25)[2014-10-27].http://www.docin.com/p-334399313.html.
[9] 董春华.中美产品缺陷法律制度基本问题比较研究[D].北京: 中国政法大学, 2009.
[10] 许传玺.侵权法重述第三版,产品责任[M].法律出版社，2006：206.
[11] MHRA. A Guide to Defective Medicinal Products.[S/OL].[2014-
10-27].http://www.mhra.gov.uk/home/groups/is-lic/documents/
publication/con007572.pdf.
[12] 赵蓓, 王准, 宋民宪. 药品警示缺陷概念分析[J]. 中药与临床, 2013(2):56-58.

[1]	MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
[2]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
[3]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[4]	TIAN Chunhua, WU Guizhi. Implementation of periodic benefit risk evaluation reports in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384.
[5]	ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390.
[6]	PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263.
[7]	XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
[8]	ZHANG Qi, CHEN Min, ZHANG Shiqing. Conditional approval of medical devices in the United States and enlightenment [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
[9]	NIE Xiaolu, TANG Shaowen, YU Jinyang, SONG Haibo, FU Zhu, SUN Feng. Interpretations of reporting recommendations intended for pharmaceutical risk minimization evaluation studies(RIMES) statement [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 524-529.
[10]	ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang. Applicability of patient registry research to regulation of medical devices [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
[11]	CUI Huanhuan, PEI Xiaojing, LI Yanrong, LIU Wendong, WANG Haixue, LAN Gongtao, WANG Tao. The practice and consideration of pharmacovigilance during clinical trials in China [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1050-1054.
[12]	SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu. Research and reflection on regulatory science developments of U.S. FDA [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
[13]	ZHANG Yajuan, JIANG Yang. Introduction and enlightenment of pharmacovigilance systems in South Korea [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1082-1086.
[14]	ZHAO Yifei, ZHAO Yan, DONG Fang, ZHENG Lijia, LI Dong, SONG Yana. Introduction and inspiration of international medical device regulators forum patient registry guidelines [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1091-1096.
[15]	BAI Hehe, NIE Xiaojing, XIA Li, MA Li, WANG Jinping, PENG Lirong. Effect evaluation of adverse drug reactions monitoring based on the Chinese hospital pharmacovigilance system [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1136-1139.